CD19 and plasma cell myeloma: In the haematologic cancers, CAR NK‐92 cells targeting BCMA, CD7, CD19 and CD33 are being investigated as a therapeutic option for patients with multiple myeloma (NCT03940833), CD7‐positive haematologic malignancies (NCT02742727), CD19‐positive lymphoid malignancies (NCT02892695) and CD33‐positive acute myeloid leukaemias (NCT02944162).